Recombinant Mouse ICOSLG/B7-H2/CD275 protein (His Tag)

Species

Mouse

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg0923

---

Validation Data Gallery

• 

  Purity of Recombinant Mouse ICOSLG was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Mouse ICOSLG protein Glu47-Lys279 (Accession# Q9JHJ8-1) with a His tag at the C-terminus.
• GeneID: 50723
• Accession: Q9JHJ8-1
• PredictedSize: 27.4 kDa
• SDS-PAGE: 37-60 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

ICOSLG, also known as B7-H2, CD275 or GL50, is a type I transmembrane glycoprotein belonging to the B7 ligand family. B7-H2/ICOSLG is extensively expressed on professional antigen-presenting cells including B cells, macrophages, and dendritic cells, as well as non-lymphoid cells including mesenchymal stem cells, endothelial cells, fibroblasts, and tumor cells. It is a specific ligand for the T-cell-specific cell surface receptor ICOS and acts as a co-stimulatory molecule. The interaction of B7-H2/ICOSLG and ICOS plays important roles in the activation, proliferation, differentiation, and cytokine production of T cells as well as in the antibody secretion from B cells during secondary immune responses.

References:

1. S Wang, et al. (2000) Blood. 96(8):2808-13.
2. S K Yoshinaga, et al. (2000) Int Immunol. 12(10):1439-47.
3. Shuang Shen, et al. (2011) Hybridoma (Larchmt). 30(4):361-8.
4. Lucie Roussel, et al. (2021) Curr Opin Immunol. 72:21-26.
5. Marius Külp, et al. (2022) iScience. 25(7):104613.